JAK2 and essential thrombocythemia: Over 95% of PV patients and over 50% of both ET and PMF patients carry the JAK2V617F mutation, which is situated in the inhibitory pseudokinase domain of JAK2 and leads to cytokine-independent JAK/STAT signaling pathway activation.